PT  - JOURNAL ARTICLE
AU  - Sardinha, Daniele Melo
AU  - Batista Lima, Karla Valéria
AU  - Lopes Ueno, Thalyta Mariany Rêgo
AU  - Rodrigues, Yan Correa
AU  - Garcez, Juliana Conceição Dias
AU  - Santos, Anderson Lineu Siqueira dos
AU  - Ferreira, Ana Lúcia da Silva
AU  - Guimarães, Ricardo José de Paula Souza e
AU  - Lima, Luana Nepomuceno Gondim Costa
TI  - The occurrence of cardiovascular complications associated with SARS-CoV-2 infection: a systematic review
AID  - 10.1101/2020.11.14.20231803
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.14.20231803
4099  - http://medrxiv.org/content/early/2020/11/16/2020.11.14.20231803.short
4100  - http://medrxiv.org/content/early/2020/11/16/2020.11.14.20231803.full
AB  - The Cardiovascular Diseases represent the main cause of death in the world, and are associated as risk factors that cause serious complications in cases of infections, such as those of the respiratory tract. In March 2020 the World Health Organization declared a pandemic for SARS-CoV-2, a new coronavirus causing severe pneumonia, which emerged in December 2019 in Wuhan, China. The objective is to investigate the occurrence of cardiovascular complications associated with SARS-CoV-2 infection. It is a systematic review, quantitative, in the databases, PubMed and Science direct, including primary studies with hospitalized patients confirmed for COVID-19 and who presented cardiovascular complications, form used tools for evaluation of quality and evidence, following the PRISMA recommendations. Results: 12 studies were included. The occurrence of cardiovascular complications was: 27.35% of the sample of 3,316 patients. Types: Acute cardiac injury 17.09%; Thromboembolism 4.73%; Heart failure 3.43%; Arrhythmias 1.77%; Brain stroke 0.33%. Mean age 61 years. Conclusions: This study showed that there are several cardiovascular complications associated with SARS-CoV-2, that the main one is the acute cardiac injury, which causes several instabilities in the cardiopulmonary system, and that it is associated with mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCNPQ CAPESAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:aAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesEstao disponiveis de forma publica